MIGRA THERAPEUTICS
Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.
MIGRA THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Status:
Active
Total Funding:
87.49 K USD
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
ParkCell
ParkCell is a development of new diagnostics and cell-based therapies for Parkinson’s Disease.
Sophia Bioscience
Sophia Bioscience develops new pharmaceutical treatments for early and metastatic cancers.
Vaxira
Vaxira is a therapeutic vaccine for the treatment of non-small cell lung cancer
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Migra Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Migra Therapeutics
More informations about "Migra Therapeutics"
Drug Innovation | Migra Therapeutics
About migra therapeutics Our Story and Mission MIGRA- Therapeutics, LLC, a biopharmaceutical company founded by Drs. Lily Yang and Lei Zhu in 2018, with a mission of clinical translation and commercialization of innovative drug delivery approaches and novel targeted nanoparticles …See details»
Team - MIGRA Therapeutics
Dr. Tianhu Sun is a Research Scientist at MIGRA-Therapeutics since March 2023. He obtained his Ph.D. from Nanjing University in 2015 and received his postdoc training in protein-protein …See details»
Migra Therapeutics - Crunchbase Company Profile & Funding
Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to. the cancer cells to deliver therapies more effectively. Migra’s system can be …See details»
Migra Therapeutics - Funding, Financials, Valuation & Investors
Organization. Migra Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 2. ... Migra …See details»
Research - MIGRA Therapeutics
MIGRA-Therapeutics, LLC, also has several preclinical pipeline projects for future clinical translation as targeted cancer imaging and therapeutic agents. The platform technologies developed …See details»
MIGRA-Therapeutics, LLC Company Profile - Dun & Bradstreet
This information is updated and provided by MIGRA-Therapeutics, LLC. The content available on the D&B Business Directory is provided "as-is" and "as-available" and may not be reviewed or …See details»
Migra Therapeutics - SPEEDA Edge
Migra Therapeutics, LLC is a biopharmaceutical company established in 2018. The company focuses on developing novel platforms for targeted therapy of advanced and drug-resistant …See details»
MIGRA-Therapeutics, LLC - VentureRadar
Dec 26, 2020 Similar Companies: FLUOROMETRIX CORPORATION USA n/a n/a. SCIGLOB INSTRUMENTS & SERVICES, LLC USA n/a n/a. InformAI USA Privately Held InformAI has a …See details»
Migra Therapeutics - CoBee Company Profile & Funding Rounds
Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called …See details»
Migra Therapeutics - Crunchbase
Migra Therapeutics is developing nanotechnology therapies for cancer. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. ... Experience the new Crunchbase, …See details»
MIGRA-Therapeutics, LLC | Georgia Company Directory
MIGRA-Therapeutics, LLC was registered on Aug 26 2018 as a domestic limited liability company type with the address 3175 Presidential Dr. Suite B, Atlanta, GA, 30340, USA. The company id …See details»
Migra-Therapeutics Company Profile -Sales, Contacts, Competitors …
Migra-Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 7 years. The Most Advanced …See details»
MIGRA-Therapeutics, LLC :: Georgia (US) :: OpenCorporates
Oct 11, 2023 Free and open company data on Georgia (US) company MIGRA-Therapeutics, LLC (company number 18115877), 1750 Haygood Dr. NE, HSRBII, Room Suite S-111, …See details»
Publications - MIGRA Therapeutics
MIGRA-Therapeutics. LLC. Home. About Us. Research. Team. News. Career Opportunities. FCOI Policy. Contact. More. KEY PUBLICATIONS. Submitted and Published Papers. …See details»
Firm | SBIR
Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... MIGRA-THERAPEUTICS LLC. …See details»
Georgia Research Alliance - GRA
Migra Therapeutics Industry: Nanotechnology therapy for cancer ... Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. …See details»
Migra Therapeutics - Updates, News, Events, Signals & Triggers
Jan 22, 2019 Migra Therapeutics is developing nanotechnology therapies for cancer. Experience the new Crunchbase, powered by AISee details»
Dr. Lei Zhu - Top Scientists
Dec 26, 2024 Dr. Zhu is an esteemed figure in the field of cancer therapeutics, drug delivery, and nanomedicine who has excelled as the co-founder and chief operating officer of MIGRA …See details»
Migra Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Migra Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 12. ... Migra …See details»
Muc16CD is a novel CAR T cell target antigen for the treatment of ...
Dec 19, 2024 G.B.L. has received research funding through a sponsored research agreement between Emory University and Merck and Co., Bristol-Myers Squibb, Boehringer Ingelheim, …See details»